Drug intelligence / Profile preview

Probac 7

Development stage: Unknown
Lead developer: Interpharma
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Probac 7 is a synbiotic dietary supplement developed and marketed by Interpharma Public Company Limited in Thailand. It contains a proprietary blend of six probiotic bacterial strains—*Lactobacillus acidophilus*, *Lactobacillus casei*, *Bifidobacterium longum*, *Bifidobacterium infantis*, *Bifidobacterium bifidum*, and *Lactococcus lactis*—combined with an oligosaccharide prebiotic. The product is designed to modulate the gut microbiota and restore intestinal balance, with indications for gut microbiome imbalance, irritable bowel syndrome (IBS), constipation, diarrhea, and allergies. Each 2g sachet contains over 50 billion colony-forming units (CFU) and is administered orally. It is registered with the Thai FDA (Registration Number: 10-3-21349-1-0002) and produced under GMP certification.

Brand names: Probac 7Probac7Probac-7

Beyond the preview

Go deeper on Probac 7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Probac 7.

Explore the full profile